Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 11:40:47-52.
doi: 10.1016/j.jdcr.2023.07.037. eCollection 2023 Oct.

Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature

Charles Dunn  1 , Victoria Griffith  2 , Alexis Coican  3 , Alexander Dane  1 , William Chow  1 , Savina Aneja  1 , Rajiv Nathoo  1 , Adam Leavitt  1 , Spencer D Hawkins  4
Affiliations
Case Reports

Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature

Charles Dunn et al. JAAD Case Rep. .
No abstract available

Keywords: alopecia; baricitinib; frontal fibrosing alopecia; janus kinase inhibitors; lichen planopilaris; ruxolitinib.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Frontal hairline of case 1 before (top) and 12 weeks after (bottom) the addition of topical ruxolitinib to her treatment regimen. Images demonstrate profound reduction of perifollicular erythema, absence of scale, and evidence of hair regrowth in previously affected areas.
Fig 2
Fig 2
Side-by-side images of temporal hairline of case 2 before (left) and 4 weeks after (right) the application of topical ruxolitinib for frontal fibrosing alopecia. Images demonstrate significant reduction of perifollicular erythema and scale.
Fig 3
Fig 3
Trichoscopy image of case 3 showing frontal hairline before (left) and 4 weeks after (right) the addition of oral baricitinib/topical ruxolitinib to her therapeutic regimen. Significant reduction in apparent erythema and scale noted with patient-endorsed absence of pruritus.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lis-Święty A., Brzezińska-Wcisło L. Frontal fibrosing alopecia: a disease that remains enigmatic. Postepy Dermatol Alergol. 2020;37(4):482–489. doi: 10.5114/ada.2020.98241. - DOI - PMC - PubMed
    1. Porriño-Bustamante M.L., Fernández-Pugnaire M.A., Arias-Santiago S. Frontal fibrosing alopecia: a review. J Clin Med. 2021;10(9):1905. doi: 10.3390/jcm10091805. - DOI - PMC - PubMed
    1. Moussa A., Bhoyrul B., Asfour L., Kazmi A., Eisman S., Sinclair R.D. Treatment of lichen planopilaris with baricitinib: A retrospective study. J Am Acad Dermatol. 2022;87(3):663–666. doi: 10.1016/j.jaad.2022.02.027. - DOI - PubMed
    1. Holmes S., Ryan T., Young D., Harries M. British Hair and Nail Society. Frontal fibrosing alopecia severity index (FFASI): a validated scoring system for assessing frontal fibrosing alopecia. Br J Dermatol. 2016;175(1):203–207. doi: 10.1111/bjd.14445. - DOI - PubMed
    1. Del Duca E., Ruano Ruiz J., Pavel A.B., et al. Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing. Br J Dermatol. 2020;183(6):1083–1093. - PubMed

Publication types

LinkOut - more resources